Attal S, Kemner J, Alvir J, Barth S, Schuessler S Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx). Cardiol Ther. 2024; 13:(2)369-378

Chan N, Teruya S, Mirabal A Temporal Outcomes of Patients Diagnosed With Transthyretin Cardiac Amyloidosis. J Card Fail. 2024; 6

Garcia-Pavia P, Sultan MB, Gundapaneni B, Sekijima Y, Perfetto F, Hanna M, Witteles R Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study. JACC Heart Fail. 2024; 12:(1)150-160

Tafamidis use in amyloid cardiomyopathy

02 June 2024
Volume 6 · Issue 6


Deborah Robertson provides an overview of recently published articles that may be of interest to non-medical prescribers. Should you wish to look at any of the papers in more detail, a full reference is provided

Last month, the research round-up provided you with an overview of a range of prescribing practices around antibiotics. This month, we look at three articles for a drug newly recommended to UK prescribers for amyloid cardiomyopathy. The first is a German study of real-world treatment patterns. The second article examines tafamidis efficacy in octogenarians with amyloid cardiomyopathy. In our final article, we will focus on temporal outcomes of patients with amyloid cardiomyopathy.

This study, published in the journal Cardiology and Therapy, sought to determine real-world prescribing patterns of tafamidis with respect to patient characteristics and persistency. Using a non-interventional, retrospective, observational cohort study methodology, the researchers accessed data from the German IQVIA LRx database. This database contains anonymised data around patient-level prescriptions for those with statutory health insurance. After extraction of data on patients aged over 18 who had received at least one prescription for tafamidis 61mg between March 2020 and August 2022, 1565 patients were identified. Baseline characteristics of those included showed that the mean age was 78.3 years and 82.4% were male. This is in line with the disease characteristics of amyloid cardiomyopathy, which was the indication of interest to the researchers.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month